Search results for "placebo-controlled"

showing 10 items of 93 documents

Monosodium benzoate hypersensitivity in subjects with persistent rhinitis

2004

Background:  Very few data are available from the literature on whether nonatopic subjects affected by persistent rhinitis may show the appearance of objective symptoms of rhinitis after the ingestion of food additives such as tartrazine (E102), erythrosine (E127), monosodium benzoate (E211), p-hydroxybenzoate (E218), sodium metabisulphite (E223), and monosodium glutamate (E620). It is still unclear whether the ingestion of food additive may cause, as well, a consensual reduction of nasal peak inspiratory flow (NPIFR). Therefore, we used a double-blind placebo-controlled (DBPC) study to evaluate this hypothesis. Patients and methods:  Two hundred and twenty-six consecutive patients (76 male…

AdultHypersensitivity ImmediateMaleAllergymedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentMonosodium glutamateImmunologyGastroenterologychemistry.chemical_compoundVasomotor RhinitisInternal medicineImmunopathologySodium BenzoatemedicineImmunology and AllergyIngestionHumansMonosodium benzoate; hypersensitivity; persistent rhinitisChildRhinitisbusiness.industryMonosodium benzoatedouble-blind placebo-controlledMiddle Agednasal peak inspiratory flowmedicine.diseasefood additivesRegimenchemistryImmunologyChronic DiseaseEtiologyFood PreservativesFemalehypersensitivityNasal CavitybusinessPulmonary Ventilationpersistent rhinitisTartrazine
researchProduct

A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease

2007

BACKGROUND: Treatment of celiac disease (CD) is based on the avoidance of gluten-containing food. However, it is not known whether trace amounts of gluten are harmful to treated patients. OBJECTIVE: The objective was to establish the safety threshold of prolonged exposure to trace amounts of gluten (ie, contaminating gluten). DESIGN: This was a multicenter, double-blind, placebo-controlled, randomized trial in 49 adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for > or =2 y. The background daily gluten intake was maintained at < 5 mg. After a baseline evaluation (t0), patients were assigned to ingest daily for 90 d a capsule containing 0, 10, or 50 mg glute…

AdultMaleGluten free diet Celiac Diseasemedicine.medical_specialtyGlutensPlacebo-controlled studyMedicine (miscellaneous)gastroenterologyDiseasedigestive systemGastroenterologyCoeliac diseaselaw.inventionRandomized controlled trialDouble-Blind Methodgluten-free dietlawInternal medicineImmunopathologyIntestine SmallMedicineHumansgluten toxicitysmall-intestinal morphometryLymphocyte CountProspective StudiesIntestinal MucosaProspective cohort studyAutoantibodiesceliac disease; gastroenterology; gluten threshold in gluten-free food; gluten threshold in gluten-free food.; gluten toxicity; gluten-free diet; small-intestinal morphometrychemistry.chemical_classificationNutrition and DieteticsDose-Response Relationship Drugbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseGlutendigestive system diseasesgluten threshold in gluten-free foodchemistryToxicityFemalebusinessceliac disease
researchProduct

Desmopressin in the Treatment of Nocturia: A Double-Blind, Placebo-Controlled Study

2007

Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-…

AdultMaleNephrologymedicine.medical_specialtyUrologyPlacebo-controlled studyAdministration OralDiuresisPlaceboDouble-Blind MethodInternal medicinemedicineHumansNocturiaDeamino Arginine VasopressinDesmopressinAdverse effectAgedAged 80 and overDose-Response Relationship Drugbusiness.industryAntidiuretic AgentsMiddle AgedSurgeryUrodynamicsTreatment OutcomeAnesthesiaFemaleNocturiamedicine.symptomSleepbusinesshormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugAntidiureticEuropean Urology
researchProduct

Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial.

2005

&lt;i&gt;Background:&lt;/i&gt; Patients with chronic urticaria (CU) frequently exhibit positive skin test reactions to autologous serum (ASST). Therapies aimed at inducing tolerance to circulating histamine-releasing factors in ASST+ CU patients, e.g. by treatment with autologous whole blood (AWB), have not yet been tested. &lt;i&gt;Objective:&lt;/i&gt; To test whether ASST+ CU patients can benefit from repeated low-dose intramuscular injections of AWB. &lt;i&gt;Methods:&lt;/i&gt; We characterized CU severity and duration, anti-Fc&lt;sub&gt;&amp;#917;&lt;/sub&gt;RI and anti-IgE expression, use of antihistamines, and quality of life in 56 CU patients (ASST+: 35, ASST–: 21) and assessed the t…

AdultMaleSerummedicine.medical_specialtyUrticariaImmunoblottingPlacebo-controlled studyEnzyme-Linked Immunosorbent AssayDermatologymedicine.disease_causePlaceboGastroenterologyAutoimmunityAutohemotherapyBlood Transfusion AutologousInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesChronic urticariaWhole bloodSkin Testsbusiness.industryReceptors IgEImmunoglobulin EMiddle AgedSurgeryAntibodies Anti-IdiotypicClinical trialTreatment OutcomePatient SatisfactionChronic DiseaseQuality of LifeAutologous serum skin testFemalebusinessFollow-Up StudiesDermatology (Basel, Switzerland)
researchProduct

Randomised placebo-controlled trial of moclobemide, cognitive–behavioural therapy and their combination in panic disorder with agoraphobia

1999

BackgroundIn the treatment of panic disorder with agoraphobia, the efficacy of pharmacological, psychological and combined treatments has been established. Unanswered questions concern the relative efficacy of such treatments.AimsTo demonstrate that moclobemide and cognitive–behavioural therapy (CBT) are effective singly and more effective in combination.MethodFifty-five patients were randomly assigned to an eight-week treatment of: moclobemide plus CBT; moclobemide plus clinical management (‘psychological placebo’); placebo plus CBT; or placebo plus clinical management.ResultsComparisons between treatments revealed strong effects for CBT. Moclobemide with clinical management was not superi…

AdultMalemedicine.medical_specialtyAdolescentPanic Disorder with AgoraphobiaMoclobemidemedicine.medical_treatmentPlacebo-controlled studyPlacebobehavioral disciplines and activities03 medical and health sciences0302 clinical medicinemental disordersMoclobemidemedicineHumans030212 general & internal medicinePsychiatryAgoraphobiaAgedAnalysis of VarianceCognitive Behavioral TherapyPanicFearMiddle Agedmedicine.diseaseCombined Modality TherapyAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTreatment OutcomeBenzamidesCognitive therapyPhysical therapyPanic DisorderPatient ComplianceFemalemedicine.symptomPsychologyAnxiety disorderFollow-Up Studiesmedicine.drugAgoraphobiaBritish Journal of Psychiatry
researchProduct

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

Repetitive low-energy shock wave treatment for chronic lateral epicondylitis in tennis players.

2004

Background There is conflicting evidence regarding extracorporeal shock wave treatment for chronic tennis elbow. Hypothesis Treatment with repetitive low-energy extracorporeal shock wave treatment is superior to repetitive placebo extracorporeal shock wave treatment. Methods Seventy-eight patients enrolled in a placebo-controlled trial. All patients were tennis players with recalcitrant MRIconfirmed tennis elbow of at least 12 months’ duration. Patients were randomly assigned to receive either active low-energy extracorporeal shock wave treatment given weekly for 3 weeks (treatment group 1) or an identical placebo extracorporeal shock wave treatment (sham group 2). Main outcome measure was …

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyPhysical Therapy Sports Therapy and RehabilitationWristPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawHand strengthLithotripsyTennis elbowmedicineHumansOrthopedics and Sports MedicineAgedPain Measurement030222 orthopedicsHand Strengthbusiness.industryEpicondylitisTennis Elbow030229 sport sciencesMiddle Agedmedicine.diseaseMagnetic Resonance ImagingSurgerymedicine.anatomical_structureTreatment OutcomeOrthopedic surgeryChronic DiseaseFemalebusinessThe American journal of sports medicine
researchProduct

Botulinum toxin vs. topical glyceryl trinitrate ointment for pain control in patients undergoing hemorrhoidectomy: a randomized trial.

2007

PURPOSE: The maximum resting pressure in the anal canal is greatly raised after hemorrhoidectomy. This increase is likely to be the cause of postoperative pain, which is still the most troublesome early problem after hemorrhoidectomy. This study was designed to compare, after hemorrhoidectomy, the effects of intrasphincter injection of botulinum toxin vs. application of glyceryl trinitrate ointment in improving wound heating and reducing postoperative pain at rest or during defecation. METHODS: Thirty patients with hemorrhoids of third and fourth degree were included in the study and randomized in two groups. Anorectal manometry was performed preoperatively and 5 and 40 days after hemorrhoi…

AdultMalemedicine.medical_specialtyManometryRestMULTICENTERPLACEBO-CONTROLLED TRIALHemorrhoidslaw.inventionInjectionsOintmentsNITROGLYCERIN OINTMENTNitroglyceringlyceryl trinitrateHemorrhoidsHEADACHERandomized controlled triallawmedicineHumansbotulinum toxinBotulinum Toxins Type AAdverse effectDefecationNEURONSPain MeasurementPain PostoperativeNITRIC-OXIDEhemorrhoidectomy CHRONIC ANAL-FISSUREbusiness.industryAnorectal manometryGastroenterologyGeneral MedicineAnal canalmedicine.diseaseDOUBLE-BLIND TRIALBotulinum toxinColorectal surgerySurgerymedicine.anatomical_structureTreatment OutcomeSPHINCTEROTOMYNeuromuscular AgentsAnesthesiaDefecationFemalebusinessmedicine.drugDiseases of the colon and rectum
researchProduct

Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction

2001

Rationale and objectives: We tested the hypothesis that the selective reversible MAO-A inhibitor moclobemide has a specific therapeutic effect on erectile dysfunction independent of its antidepressive properties. Methods: In a double-blind placebo controlled study, 12 male outpatients suffering from psychogenic erectile dysfunction without any other psychiatric disorder were investigated. Based on comprehensive diagnosis before the beginning of the study, organic factors relevant for sexual function were excluded. The treatment period was 8 weeks. Half the patients received 450 mg moclobemide during the first week, and 600 mg afterwards; the others received placebo. Apart from assessment of…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsMoclobemidePlacebo-controlled studyPlaceboDouble-Blind MethodErectile DysfunctionInternal medicineMoclobemidemedicineHumansPsychogenic diseasePharmacologyAnalysis of VariancePenile ErectionTherapeutic effectElectroencephalographyMiddle Agedmedicine.diseaseSurgeryErectile dysfunctionClinical Global ImpressionPsychologySexual functionmedicine.drugPsychopharmacology
researchProduct

Abdominal Ultrasound Does Not Reveal Significant Alterations in Patients With Nonceliac Wheat Sensitivity

2017

Abstract GOALS: The goal of this study was (A) to evaluate abdominal ultrasound signs in nonceliac wheat sensitivity (NCWS) patients for features useful in diagnosis and (B) to compare these aspects with those of celiac patients to assess whether ultrasound can be useful in the differential diagnosis between NCWS and celiac disease (CD). BACKGROUND: NCWS diagnosis is difficult as no biomarkers of this condition have as yet been identified. In CD ultrasound aspects have been identified that have a good diagnostic accuracy. STUDY: We prospectively recruited 45 NCWS patients (11 males, 34 females; mean age 35.7 y). Three control groups were included: (A) 99 age-matched CD patients; (B) 18 pati…

AdultMalemedicine.medical_specialtyNon-Celiac Wheat sensitivity Celiac Disease Abdominal Ultrasound Seronegative celiac disease Double-blind placebo-controlled challengeSettore MED/09 - Medicina InternaGlutensWheat HypersensitivityGastroenterology030218 nuclear medicine & medical imagingDiagnosis DifferentialIrritable Bowel SyndromeDiet Gluten-FreeYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodInternal medicineElimination dietAbdomenAscitesmedicineHumansMesenteric lymph nodesProspective StudiesProspective cohort studyIrritable bowel syndromeUltrasonographybusiness.industryUltrasoundGastroenterologyMiddle Agedmedicine.diseaseCeliac Diseasemedicine.anatomical_structureFemale030211 gastroenterology & hepatologyGluten freemedicine.symptomDifferential diagnosisbusiness
researchProduct